Introduction
Urothelial cell carcinoma (UCC) of the bladder is the fifth most common cancer in the world, with 357 000 cases diagnosed yearly worldwide (Parkin et al., 2005) . The majority (75%) of these tumours are non-invasive well-differentiated tumours (that is, pTa and pT1) that can be controlled by transurethral resection of the bladder wall. However, up to 70% of the patients with a superficial UCC will have recurrences after its removal, and 10-15% will progress to invasive UCC. Even in those that do not progress, regular surveillance by cystoscopy is required, making bladder cancer one of the most expensive and labour-intensive cancers to treat.
A number of genetic and epigenetic alterations involved in bladder tumorigenesis have been identified, including activating mutations in FGFR3 and RAS family genes, amplification of ERBB2, and loss of the TP53, RB1 and phosphatase and tensin homologue (PTEN) tumour suppressors (Schulz, 2006; Luis et al., 2007; Cordon-Cardo, 2008; Diaz et al., 2008) . However, the role of the Wnt pathway in UCC is yet to be resolved.
The Wnt/b-catenin signalling pathway has a crucial role in embryogenesis, cell differentiation and tumorigenesis. Wnt's are secreted glycoproteins that function as ligands to stimulate receptor-mediated signal transduction pathways in both vertebrates and invertebrates (Moon et al., 2004) . In the absence of a Wnt signal, cytoplasmic b-catenin is phosphorylated and degraded in a complex of proteins. The complex, which causes the phosphorylation of b-catenin and thus targets it for degradation, is a multi-protein scaffolding complex, consisting of adenomatous polyposis coli (APC), glycogen synthase kinase (GSK) 3b, casein kinase 1 and axin. Following Wnt pathway activation (through the binding of a Wnt ligand to the frizzled transmembrane receptor), GSK3 is inactivated and b-catenin is no longer phosphorylated and targeted for degradation. As a result, b-catenin accumulates in the cytoplasm and enters the nucleus in which it binds to T-cell factor/ lymphocyte enhancement factor family members and transcriptionally regulates Wnt target genes, which include cyclin D1 and c-myc (canonical Wnt signalling pathway) (He et al., 1998; Tetsu and McCormick, 1999; Bienz and Clevers, 2000; Polakis, 2000) .
Germ-line and somatic mutations of APC are found in the majority of colorectal cancers (Kinzler et al., 1991; Cottrell et al., 1992; Rubinfeld et al., 1993) . However, in the case of bladder carcinoma, controversy surrounds the occurrence of somatic mutations in key components of the pathway; Wnt (Miyamoto et al., 1996; Bohm et al., 1997; Stoehr et al., 2002; Urakami et al., 2006a) and b-catenin (Shiina et al., 2001 (Shiina et al., , 2002 Burger et al., 2008) . Many of these studies have shown immunohistochemical (IHC) upregulation of b-catenin, the key protein in this pathway (Shimazui et al., 1996; Garcia et al., 2000; Nakopoulou et al., 2000; Zhu et al., 2000; Kashibuchi et al., 2006) . Urakami et al. (2006b) showed that CpG hypermethylation of Wnt inhibitory factor-1 was a frequent occurrence in bladder tumorigenesis. Most recently Kastritis et al. (2009) have shown missense (13%) and frameshift (3%) deletions in APC adjacent to the b-catenin binding sites in bladder tumours. They found either APC mutations or b-catenin accumulation resulted in shorter disease-free interval and a shorter disease-specific survival in multivariate analysis. Similarly, epigenetic silencing of the four secreted frizzled receptor proteins antagonists of the Wnt signalling pathway, has been shown as an independent predictor of invasive bladder cancer (Marsit et al., 2005) . In a cohort of 355 patients, a linear relationship between the magnitude of the risk of invasive disease and the number of secreted frizzled receptor protein genes methylated was observed (Po0.0004) with a subsequent reduction in overall survival (Po0.0003). Therefore, these studies suggest a key role of deregulation of Wnt signalling in bladder cancer, a finding that we test in this study.
Mutations of the tumour suppressor PTEN have been described in many tumours (Salmena et al., 2008) , including deletion of the locus in bladder cancers (Teng et al., 1997; Aveyard et al., 1999; Tsuruta et al., 2006) . These deletions are absent/rare in superficial tumours, but occur frequently in invasive bladder cancers. Previously, inactivation of PTEN in the murine urothelium has been shown to result in widespread hyperplasia (Tsuruta et al., 2006; Yoo et al., 2006) , and recently it has been shown that combined deletion of Pten and Trp53 in the murine urothelium results in aggressive UCC, which is dependent on mammalian target of rapamycin (mTOR) signalling (Puzio-Kuter et al., 2009) .
In this study, we show that activation of Wnt signalling pathway in the absence of PTEN potently promotes UCC in vivo.
Results b-Catenin overexpression leads to benign hyperproliferation of the urothelium To promote deregulated Wnt signalling, we used mice that carry a dominant allele of the b-catenin gene in which exon3 is flanked by loxP sequences (Harada et al., 1999) . On addition of Cre recombinase, exon3 is deleted, thus activating Wnt signalling, as this exon contains the residues that are phosphorylated by GSK3b, leading to b-catenin degradation. Thus, b-catenin will accumulate and promote Wnt signalling (Moon et al., 2004) . To achieve urothelial specific expression of activated b-catenin, we interbred these mice with mice carrying a uroplakin II (UroII) CRE transgene (Mo et al., 2005; He et al., 2009) . UroII is a protein localized at the apical surface of the urothelium and is important for its permeability barrier function (Zhang et al., 1999) . It is expressed throughout the urothelial layers in mice (Mo et al., 2005) . The UroII promoter has been reported to successfully drive the expression of proteins including SV40 large T antigen and Ha-ras (Zhang et al., 2001; Mo et al., 2007) . Previous studies have shown that the UroIICRE þ mice show bladder-specific recombination (Zhang et al., 1999) . To confirm this, and report levels of recombination, we inter-crossed the UroIICRE þ mice with mice carrying the Z/EGFP reporter transgene (Novak et al., 2000) . In the Z/EGFP reporter mouse, the Z/EGFP transgene results in the expression of b-galactosidase by most tissues by a b-geo insert, which is flanked by loxP sites. The presence of Cre recombinase results in the excision of the b-geo, activating the constitutive expression of green fluorescent protein (GFP). IHC for GFP shows the expression of enhanced GFP in the urothelial lining of the bladder and ureters (Figure 1g ; Novak et al., 2000) .
First, we used mice carrying one or two copies of the b-catenin exon3 allele, to test whether the amplitude of the Wnt deregulation was important, as levels of deregulated Wnt signalling have been shown to be important in other organs such as the mammary gland (Howe and Brown, 2004) . To investigate the phenotype of b-catenin activation within the bladder, we used
and UroIICRE þ b-catenin exon3/exon3 mice when they were 3-month old. In mice carrying one or two copies of the b-catenin exon3 allele there was a clear phenotype in the bladder epithelium, with all mice developing areas of urothelial hyperplasia (Figures 1a and d) . To confirm that this was due to the activation of b-catenin, we performed IHC for b-catenin and saw a marked upregulation of nuclear b-catenin (Figures 1b and e) , as well as Wnt target gene c-Myc (data not shown). To confirm the lesions were hyperproliferative, we then stained for the proliferation markers Ki67 and bromodeoxyuridine (BrdU), both of which we found to be upregulated (Figures 1h and i) . No differences in proliferation as assessed by BrdU positivity were observed in mice carrying either one or two copies of the b-catenin exon3 allele (data not shown).
Given that mice formed hyperproliferative lesions, we predicted that mice would develop UCC as they age. To test this, we used UroIICRE
/exon3 mice when they were 18 months of age. Significantly, no mice developed UCC within this time course and when bladders from these 18-month-old mice were examined they appeared equivalent to those at 3 months with a b-Catenin synergizes with PTEN loss to cause UCC I Ahmad et al number of hyperproliferative lesions that had not progressed to cancer (Supplementary Figure 1) . There was however a small yet significant increase in the numbers of lesion per bladder (Po0.001; Supplementary Figure 1 ).
PTEN tumour suppressor pathway is activated in the bladder lesions
We next investigated the pathways that were constraining tumour progression within the areas of urothelial hyperplasia. UCCs can be broadly separated into two molecular pathways (Wu, 2005; Luis et al., 2007) . In one pathway, patients have either FGFR3 or HRAS mutations and they develop superficial papillary disease, which often has a good prognosis. The other tumour subtype has a more aggressive phenotype, leading to muscle invasion and ultimately metastatic disease. These tumours have often lost p53 and/or have an activation of the PI3 kinase signalling pathway. Indeed, a recent study has shown that low PTEN levels correlate with a poor prognosis in human bladder cancer (Puzio-Kuter et al., 2009 ). This has recently been modelled in the mouse using adenoviral Cre infections into the bladder. Mice either singly mutant for Pten or Trp53 did not develop tumours, however double knockout mice developed metastatic urothelial cancer. Thus, we studied the expression of candidate molecules from the p53 and PTEN tumour suppressor pathways within lesions from the UroIICRE Histology from 3-month-old UroIICRE þ b-catenin exon3/exon3 mice. Hematoxylin and eosin reveals development of hyperplastic lesions in the urothelium (black/red arrows) (a), of which a close-up (red arrows) is observed in (d). Immunohistochemistry shows strong upregulation of nuclear b-catenin (b, e) and PTEN (c, f) in these hyperplastic areas. IHC for GFP reveals evidence of recombination (g). We can see that these lesions show upregulation of markers of proliferation; BrdU (h) and . Within these lesions we see minimal pAKT (Ser473) (j) and pmTOR (k) signal. We also notice significant upregulation of p21 (l). Red bar measures 1000 mm ( Â 4 objective), black bar measures 200 mm ( Â 20 objective).
b-Catenin synergizes with PTEN loss to cause UCC I Ahmad et al minimal pAKT and pmTOR staining (Figures 1j and k) , suggesting that the PTEN tumour suppressor was potentially blocking tumour progression. In contrast to a large increase in PTEN, there was only a modest increase in the levels of nuclear p53 (not shown) though one of the targets of p53, p21, was highly upregulated within the lesions of the mice (Figure 1l ).
PTEN upregulation functions to block b-catenin-driven urothelial proliferation As the Uroplakin Cre recombinase is expressed throughout development of the urothelium, it is difficult to assess whether the upregulation of PTEN is a direct consequence of b-catenin accumulation. Therefore, we next investigated the consequence of inducibly activating Wnt signalling in the adult urothelium. To perform this, we used mice carrying the cytochrome p450-inducible AhCreER T transgene. Following administration of both b-naphthoflavone and tamoxifen, this yields Cre-mediated recombination within the urothelium of the bladder (as well as the intestine). Figures 2a and b show recombination in the bladder as evidenced by GFP signalling identified by OV100 imaging (ex vivo) and IHC for GFP in AhCreER T Z/EG reporter mice 7 days following induction. To investigate the effect of acutely activating Wnt signalling in the adult bladder, we intercrossed AhCreER T mice with mice carrying the inducible knockout Apc 580S allele from hereafter known as Apc fl (Shibata et al., 1997) . Significantly, examination of the bladders from AhCreER T APC fl/fl mice 7 days following induction revealed development of urothelial lesions that phenocopied those from our UroIICRE and g ). Importantly, once again very high levels of PTEN were observed within these lesions (Figure 2i ) with minimal upregulation of pAKT (Figure 2k ). To confirm that this was because of increased levels of Wnt signalling, we also activated Wnt signalling by deleting both copies of GSK3. Bladders from induced AhCreER MacAulay et al., 2007; Patel et al., 2008) . Using this induction regime, it was found that mice developed hyperplastic intestinal epithelium, which precluded long-term tumour experiments; however, in mice aged up to 4 months bladder lesions still remained small and did not progress to cancer, suggesting PTEN was once again blocking tumorigenesis.
To test the role PTEN was having immediately following Apc loss in the urothelium, we generated Figure 3E) . Thus, PTEN accumulation following b-catenin activation was found to limit proliferation. We again were unable to further analyse the AhCreER T APC fl/fl Pten fl/fl mice as these mice became ill rapidly after induction due to intestinal disease at day 8.
PTEN loss cooperates with b-catenin activation to promote UCC formation To test whether this block of proliferation by PTEN was suppressing tumorigenesis, we inter-crossed UroIICRE þ b-catenin exon3/exon3 mice with mice carrying a conditional inactivatable Pten allele (where exons 4 and 5 are flanked by loxp sites) (Lesche et al., 2002) . A recent study using adenoviral Cre delivery to the bladder has shown that deletion of Pten alone in the murine urothelium is not sufficient to promote bladder cancer formation (Puzio-Kuter et al., 2009 Figure 4A and B) . To confirm that Pten was deleted in these mice, we stained for PTEN levels by IHC and found a downregulation of the PTEN protein in bladders from UroIICRE Figure 4E and F). These data are consistent with our studies within the intestinal epithelium in which Pten deletion was not sufficient to promote tumorigenesis and only modestly affected the levels of pAKT (Marsh et al., 2008) . To test the cooperation of b-catenin and PTEN loss, we generated the following cohorts: UroIICRE
Pten fl/fl (n ¼ 20, 16, 24 and 21, respectively). We then performed two sets of experiments; first, we collected mice at 3 months of age and analysed the bladder phenotypes and second, we aged mice until tumour development. At 3 months of age, hyperplastic lesions (scored from three hematoxylin and eosin cross-sections of each mouse, with three mice in each cohort) were observed at an increased frequency in doubly mutant mice compared with mice carrying only b-catenin mutation (Figure 3a ; Supplementary  Figure 1) .
Second, in contrast to the UroIICRE þ b-catenin
Pten fl/fl mice and UroIICRE þ b-catenin exon3/ þ Pten fl/fl mice rapidly developed symptoms of bladder tumorigenesis; abdominal swelling, haematuria (blood in the urine) and hunching (Figure 3b ). On necropsy, we observed bladder tumours (Figure 3c ), and histologically, lesions had now progressed to papillary carcinoma (Figures 4a and b) . We found no evidence of metastasis in any of our models. These double mutant mice showed no increase in invasiveness. Consistent with Pten deletion, the tumours that developed showed complete loss of PTEN protein and strong activation of pAKT (Ser473) (Figures 4c and d) . Tumours also showed a nuclear upregulation of bcatenin and Ki-67 (Figures 4e and f) . The number of proliferating cells within tumours (identified by Ki-67 and BrdU IHC) was much higher than levels found in the UroIICRE þ b-catenin exon3/exon3 mice (data not shown), possibly explaining why lesions do not progress in the single mutant.
Of the targets downstream of pAKT
Ser473
, we also see a dramatic increase in p-mTOR Ser2448 (Figure 4g ), suggesting that mTORC activation is a key component of tumorigenesis in this model. Importantly, total levels of AKT and mTOR are unchanged (Supplementary Figure  5) , suggesting that loss of PTEN stimulates strong PI3 kinase signalling only once b-catenin is additionally activated within the bladder epithelium. These studies predict that there is sufficiently low endogenous PI3 kinase signalling within the bladder to preclude AKT phosphorylation even in the absence of PTEN. In contrast, a prediction of our data is that activation of the Wnt signalling pathway stimulates PI3 kinase activity; however the increase in PTEN protein blocks most downstream activation of p-AKT and p-mTOR. To examine this a little more closely, we examined a number of candidate ligands and receptors in UroCRE b-catenin exon3/exon3 mutant mice that should stimulate PI3 kinase activity, and found that type I insulin growth factor receptor-b subunit (IGF-IRb) was upregulated (Figure 4i ). These data would therefore suggest that the modest increase in p-AKT/p-mTOR signalling might be contributing to the increase in proliferation within the small lesions. To test this, we treated 3-month-old UroIICRE
mice (which at this time have fully established hyperproliferative lesions) with rapamycin (10 mg/kg, i.p., daily) or vehicle for 4 weeks. We were able to show a consistent downregulation of BrdU positivity/lesion (Po0.05) in the rapamycin-treated cohort compared with the vehicle controls (Supplementary Figure 2) . Interestingly in tumours arising in double mutant UroIICRE þ b-catenin exon3/exon3 Pten fl/fl bladders, there was an even more marked accumulation of IGF-IRb (Figure 4j) , suggesting further stimulation of PI3 kinase signalling.
Consistent with our tumours being dependent on PI3-kinase signalling, there was no upregulation of pERK1/2 in the tumours (Figure 4h ). By 12 months of age, a small subset of the UroIICRE þ b-catenin
Pten fl/ þ mice and UroIICRE þ b-catenin exon3/ þ Pten fl/ þ mice had developed tumours. This was presumably because of the loss of the remaining Pten allele, as staining for PTEN was absent from the tumours (Figure 4k ). Pten fl/fl mice would remain dependent on mTOR even if they were fully established. Therefore, we treated
Pten fl/fl mice at 6 months of age, when mice had a detectable tumour using Vevo 770 ultrasound (Visulasonics, Toronto, Canada), with rapamycin (10 mg/kg, i.p., daily) or with vehicle (n ¼ 3). Remarkably, we were able to demonstrate regression of tumour bulk between initiation and the end of treatment (Figures 5a-d) . All mice on treatment survived the 4-week experiment, however in the vehicle-treated mice cohort, two mice had to be killed early (7 and 11 days) because of tumour burden. IHC for p-mTOR Ser2448 revealed significant upregulation of this pathway in
Pten fl/fl mice (Figure 5e ). However, when treated with 4 weeks of rapamycin, we noticed regression of the lesions and downregulation of mTOR activation, as well as downregulation of two of its targets p-4EBP1 and p-S6 kinase (Thr421/Ser424) (Figures 5e and f; Supplementary Figure 6 ). We noticed a statistically significant reduction in the BrdU-positive cells in the tumours from the rapamycin-treated mice compared with the vehicle controls (Po0.05, MannWhitney test) (Supplementary Figure 7) .
Human UCC show correlation between Wnt activation and PTEN loss In human urothelial cancer, a number of studies have suggested that Wnt signalling is important. Of particular note is the demonstration that nuclear b-catenin is associated with a poor prognosis and methylation of the inhibitors of Wnt signalling, the secreted frizzled related proteins, act as markers of a bad prognosis (Marsit et al., 2005; Urakami et al., 2006a, b) . Indeed the methylation of these proteins has been suggested as a marker of invasive bladder carcinoma.
We next looked at human bladder UCC using a tissue microarray of 80 cases, 60 UCC (transitional cell carcinomas) and 20 benign controls (Folio Biosciences, Kirkegaard et al., 2006) . This is a further indication that loss of PTEN/upregulation of pAKT is essential for Wnt-promoted UCC to progress.
Discussion
There has been much debate over the functional role of Wnt pathway activation in cancers that do not have high frequencies of Wnt pathway mutations, for example, Apc inactivating mutations or b-cateninactivating mutations. Thus, this necessitates proof-ofprinciple genetic studies to examine whether activation of Wnt signalling can functionally promote tumorigenesis.
In this study, we have shown that although b-cateninactivating mutations cannot initiate bladder carcinogenesis, it dramatically cooperates with PTEN loss to promote bladder tumorigenesis in the mouse. This finding that b-catenin activation (or Apc loss) is not sufficient to promote UCC formation potentially explains why people and mice that carry germ-line mutations of APC do not develop UCC.
The strong cooperation between deregulated Wnt signalling and PTEN loss we observed suggests that the significance of Wnt signalling in human bladder cancer may have been underestimated. On an average, up to a quarter of bladder tumours are thought to exhibit nuclear b-catenin (Kastritis et al., 2009 ), a finding we confirm in this study, though very few of these tumours exhibit either Apc or b-catenin mutations. Instead, epigenetic inactivation of negative regulators of the Wnt pathway such as secreted frizzled related proteins have been shown to occur (Marsit et al., 2005) . One of the problems with assaying Wnt pathway activation b-Catenin synergizes with PTEN loss to cause UCC I Ahmad et al in vivo (in the absence of mutation) is that this relies on IHC staining for nuclear b-catenin, which can produce variable results depending on tissue fixation protocols. Therefore, a future challenge would be to identify those tissue-specific transcriptional targets of the Wnt pathway as biomarkers to define those tumours that exhibit deregulated Wnt signalling. Identification of cancers with deregulated Wnt signalling has become particularly pertinent due to the development of a number of novel therapeutic agents that target this pathway. Recently, antibody-based therapies have been developed that target cell-surface molecules of the Wnt pathway (such as Wnt's and Frizzled's) that are overexpressed in disease (You et al., 2004; Nagayama et al., 2005) . Thus, tumours with deregulated Wnt signalling in the absence of pathway mutations may be responsive to antibodies that inhibit Wnt signalling through blocking ligand binding, such as Frizzled8CRD-hFc (DeAlmeida et al., 2007) . One key question that remains is whether tumours that are not initiated by Wnt pathway mutations will be dependent on this pathway and future pre-clinical in vivo studies will be required to test this notion.
Numerous studies have proposed cross talk between the Wnt and PI3 kinase pathways, both at the molecular and the functional level. This is the first study to identify PTEN as directly downstream of the Wnt pathway. Given that we observed patients with high levels of p-AKT and b-catenin, combined inhibition of the pAKT/mTOR and Wnt pathways may be efficacious in these patients. Indeed, given the recent study by Puzio-Kuter et al. (2009) showing bladder tumours promoted by combined PTEN and p53 loss were sensitive to rapamycin and our data showing the rapid Pten fl/fl tumours with rapamycin, it suggests that bladder tumours may be particularly susceptible to mTOR inhibition. Moreover, recent studies have shown that Apc loss increases levels of mTOR (Fujishita et al., 2008) , suggesting those tumours with activation of both the PI3 kinase and Wnt signalling pathways may be highly sensitive to mTOR inhibition.
It is often proposed that the inhibitory phosphorylation of GSK3 by AKT may allow the activation of Wnt signalling. If this was the case, one would argue that PTEN loss alone should be sufficient to activate Wnt signalling and numerous studies have shown that this is not the case (including this study) (Salmena et al., 2008) . Moreover, two key studies suggest that the phosphorylation of GSK3 by AKT does not affect Wnt signalling. First, 'knock-in' mice in which the AKT phosphorylation sites on GSK3a (Ser21) and GSK3b (Ser9) were converted to alanine did not elevate Wnt signalling (McManus et al., 2005) . Second, a recent study has shown that the Wnt pool of GSK3 is physically distinct from the AKT pool (Ng et al., 2009) . Our data here show it is only in the complete genetic absence of both GSK3a and GSK3b that Wnt signalling is deregulated (Supplementary Figure 3) .
Taken together, we are first to examine the causative role of b-catenin in the formation of UCC in vivo and provide definitive evidence that activating mutations in the Wnt pathway promote UCC when combined with other tumour suppressor mutations.
Materials and methods

Mice
UroplakinII Cre mice (UroIICRE þ ) (Zhang et al., 1999) Table demonstrating proportions of cores that demonstrate combinations of upregulation and downregulation of b-catenin and PTEN (upregulation is classified as X100 and downregulation as o100 using the histoscore technique) (d). Scatterplot demonstrating correlation between b-catenin and pAKT (e). Each core measures 1.5 mm.
b-Catenin synergizes with PTEN loss to cause UCC I Ahmad et al as described below. The AhCreER T mice were also used and inter-crossed with mice harbouring Z/EGFP (Novak et al., 2000) , APC fl/fl (Shibata et al., 1997) and Pten fl/fl (Lesche et al., 2002) mice. AhCreER T mice were inter-crossed with GSK3ab fl/fl (MacAulay et al., 2007; Patel et al., 2008) mice. Mice were genotyped by PCR as previously described (Shibata et al., 1997; Harada et al., 1999; Zhang et al., 1999; Novak et al., 2000; Lesche et al., 2002; Ireland et al., 2004; Kemp et al., 2004) . Mice were of a mixed background and littermates were used as control mice. All experiments were carried out in accordance with UK animal regulations.
When bladders were excised they were all emptied of urine, before being placed in formalin for overnight fixation, before paraffin embedding. All bladders were processed and cut in the same manner by a single histology technician to aid standardization.
